Skip to main
VKTX
VKTX logo

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. is strategically positioned within the biopharmaceutical sector, focusing on metabolic and endocrine disorders, with a robust clinical program pipeline that includes promising products like VK2809 and VK0214. The increasing interest in independent, late-stage metabolic players in the industry, combined with Viking's advanced maturity and data strength, enhances the company's appeal for potential partnerships and financing opportunities. Furthermore, key clinical updates and a focus on new products such as VK2735, which offers a potentially advantageous monthly dosing regimen, are expected to bolster investor sentiment ahead of significant clinical milestones.

Bears say

Viking Therapeutics Inc. is facing significant industry-standard risks, including potential unexpected outcomes from clinical trials and regulatory uncertainties that could adversely affect its pipeline of metabolic and endocrine disorder treatments. Additionally, the company operates in increasingly complex and price-sensitive commercial markets, which may impact the viability and profitability of its product candidates such as VK2809, VK5211, and VK0214. Heightened scrutiny of licensing deals, particularly in the context of US/China relations, further complicates the company's strategic position and may contribute to a challenging operating environment.

Viking Therapeutics (VKTX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 14 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.